Gummy Vitamin recall: FDA Flags B12 supplements sold on Amazon, Aldi — See which brands are affected
Details of the Recalled Products
Welby (sold at Aldi): 1,000 mcg B12, 140-count bottle; UPC: 4099100290868
Berkley Jensen (sold at BJ's Wholesale Club): 1,000 mcg B12, 250-count bottle; UPC: 888670132487
VitaGlobe (sold online, including Amazon): Extra Strength B12, 60-count bottle; UPC: 850005214670
No Reports of Illness Yet, Recall Issued as Precaution
Live Events
Routine Testing Triggered the Recall
What Consumers Should Do
FAQs
Why were the B12 gummy vitamins recalled?
Have there been any reported health incidents linked to the gummy vitamin recall?
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
A batch of gummy vitamins sold across major U.S. retailers including Amazon, Aldi, and BJ's Wholesale Club has been voluntarily recalled following the detection of a potentially dangerous undeclared allergen. The move was announced by Vita Warehouse Corp. on June 12, following standard allergen testing procedures initiated by one of the retailers.The recall applies to specific lots of B12 gummy vitamins marketed under the brand names Welby , Berkley Jensen, and VitaGlobe . The U.S. Food and Drug Administration (FDA) confirmed in a public advisory that the recalled products may contain traces of peanuts, posing a risk to individuals with allergies or severe sensitivity.The affected Gummy Vitamins, as mentioned in a report by USA Today, have been identified as follows:All three products belong to the Lot Number 248046601 and carry an expiration date of October 2026. The packaging consists of clear bottles with white caps and variations in label colors. The lot number and expiry date are printed on the bottom of the bottles.According to the FDA, there have been no confirmed illnesses or allergic reactions linked to the consumption of the affected vitamin gummies. Nonetheless, the recall was issued 'out of an abundance of caution,' especially in light of the potentially severe consequences for peanut-allergic consumers.Peanut allergies can lead to life-threatening reactions, including anaphylaxis. The FDA has urged consumers with known sensitivities to immediately discontinue use of the identified products.The allergen was flagged during routine label-verification testing by Aldi. Although Vita Warehouse Corp.'s own testing did not detect peanut residue, the single adverse result was enough to initiate a recall. The FDA stated that the retailer's protocol included verification of a 'does not contain peanuts' claim, which one product reportedly failed.Importantly, the agency has clarified that no other products under the Welby, Berkley Jensen, or VitaGlobe brand names are impacted by this recall.Customers in possession of the recalled products—particularly those with peanut allergies—are advised to return the items to their point of purchase for a full refund or dispose of them safely. The FDA has emphasized that anyone experiencing symptoms of an allergic reaction should seek immediate medical care.Consumers with questions can reach Vita Warehouse Corp. via their toll-free helpline at 1-855-214-0100 (Monday through Friday, 7:30 a.m. to 4:00 p.m. EST).The recall was issued after routine testing detected the presence of an undeclared allergen—peanut residue—in one of the products. While no illnesses have been reported, the recall was initiated as a precaution to protect consumers with peanut allergies.No, the U.S. Food and Drug Administration (FDA) confirmed there have been no illnesses or allergic reactions reported so far. The recall was issued as a preventive measure.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
Gummy Vitamin recall: FDA Flags B12 supplements sold on Amazon, Aldi — See which brands are affected
Details of the Recalled Products Welby (sold at Aldi): 1,000 mcg B12, 140-count bottle; UPC: 4099100290868 Berkley Jensen (sold at BJ's Wholesale Club): 1,000 mcg B12, 250-count bottle; UPC: 888670132487 VitaGlobe (sold online, including Amazon): Extra Strength B12, 60-count bottle; UPC: 850005214670 No Reports of Illness Yet, Recall Issued as Precaution Live Events Routine Testing Triggered the Recall What Consumers Should Do FAQs Why were the B12 gummy vitamins recalled? Have there been any reported health incidents linked to the gummy vitamin recall? (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel A batch of gummy vitamins sold across major U.S. retailers including Amazon, Aldi, and BJ's Wholesale Club has been voluntarily recalled following the detection of a potentially dangerous undeclared allergen. The move was announced by Vita Warehouse Corp. on June 12, following standard allergen testing procedures initiated by one of the recall applies to specific lots of B12 gummy vitamins marketed under the brand names Welby , Berkley Jensen, and VitaGlobe . The U.S. Food and Drug Administration (FDA) confirmed in a public advisory that the recalled products may contain traces of peanuts, posing a risk to individuals with allergies or severe affected Gummy Vitamins, as mentioned in a report by USA Today, have been identified as follows:All three products belong to the Lot Number 248046601 and carry an expiration date of October 2026. The packaging consists of clear bottles with white caps and variations in label colors. The lot number and expiry date are printed on the bottom of the to the FDA, there have been no confirmed illnesses or allergic reactions linked to the consumption of the affected vitamin gummies. Nonetheless, the recall was issued 'out of an abundance of caution,' especially in light of the potentially severe consequences for peanut-allergic allergies can lead to life-threatening reactions, including anaphylaxis. The FDA has urged consumers with known sensitivities to immediately discontinue use of the identified allergen was flagged during routine label-verification testing by Aldi. Although Vita Warehouse Corp.'s own testing did not detect peanut residue, the single adverse result was enough to initiate a recall. The FDA stated that the retailer's protocol included verification of a 'does not contain peanuts' claim, which one product reportedly the agency has clarified that no other products under the Welby, Berkley Jensen, or VitaGlobe brand names are impacted by this in possession of the recalled products—particularly those with peanut allergies—are advised to return the items to their point of purchase for a full refund or dispose of them safely. The FDA has emphasized that anyone experiencing symptoms of an allergic reaction should seek immediate medical with questions can reach Vita Warehouse Corp. via their toll-free helpline at 1-855-214-0100 (Monday through Friday, 7:30 a.m. to 4:00 p.m. EST).The recall was issued after routine testing detected the presence of an undeclared allergen—peanut residue—in one of the products. While no illnesses have been reported, the recall was initiated as a precaution to protect consumers with peanut the U.S. Food and Drug Administration (FDA) confirmed there have been no illnesses or allergic reactions reported so far. The recall was issued as a preventive measure.
Time of India
10 hours ago
- Time of India
Elon Musk passes ketamine test—here's what the drug is and why it raised eyebrows
Credit: X Elon Musk isn't new to controversy, but this time the firestorm came in the form of a drug test. After weeks of speculation following a New York Times report accusing him of heavy ketamine and drug use during his time in the Trump administration as head of the Department of Government Efficiency (DOGE), Musk fired back in his signature style—by posting his urine test results online with just one word: 'Lol. ' The test, taken recently, shows negative results for ketamine and several other substances, directly challenging claims that he regularly used ecstasy, mushrooms, Adderall, and ketamine to the point of suffering bladder damage. Musk doubled down on his denial earlier, calling the NYT article 'lies' and clarified that while he had tried prescription ketamine years ago, it was for mental health purposes and he hadn't taken it since. So what's the big deal about ketamine, and why is a clean test so significant? Understanding ketamine: From surgical anesthetic to controversial antidepressant Ketamine is classified as a Schedule III non-narcotic controlled substance in the United States. It was approved by the Food and Drug Administration (FDA) strictly as a general anesthetic—used alone or in combination with drugs like nitrous oxide. Doctors typically use it in surgical or emergency settings, as a sedative. But ketamine's uses have expanded. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Unfriendliest Countries in the World, Ranked BigGlobalTravel Undo Off-label, doctors are prescribing it for mental health conditions like depression and anxiety, especially in people who don't respond well to traditional medications. While the FDA hasn't formally approved ketamine for these uses, ongoing research shows it can provide rapid relief from symptoms of depression and anxiety—though those effects may be short-lived. A 2023 review emphasized that the effectiveness of ketamine treatment depends on dose and type, with higher doses often leading to better short-term symptom relief. However, a 2022 review on ketamine for anxiety noted that results were mixed, with many people experiencing a return of symptoms within two weeks. How long does Ketamine stay in the body? Ketamine is found in both liquid and powder forms. In medical settings, it's administered as a clear liquid injection. In recreational settings, powdered ketamine—typically off-white—is snorted in lines or mixed into marijuana or tobacco. It's also sometimes added to drinks. As for detection, urine tests are the most common method because they are affordable, easy, and fairly accurate. Here's how long ketamine is detectable: Urine: Up to 3 days after single use; 5–7 days with regular use; up to 30 days in rare chronic-use cases Blood: Around 24 hours Saliva: Up to 72 hours Hair: Up to 90 days A negative urine test, like the one Musk posted, means there's no detectable ketamine or its metabolites in the body above the lab's threshold. This strongly indicates no recent use, especially within the past few days or weeks. Medical uses of ketamine: More than just an anesthetic Besides general anesthesia, ketamine is being explored and used (off-label) for several conditions. Here's a quick look at how and where doctors may prescribe ketamine: Pain treatment (low-dose): For trauma, fractures, abdominal pain, limb injuries, and chronic lower back pain Status epilepticus: In life-threatening seizures that don't respond to other anti-seizure drugs Depression: Especially treatment-resistant depression. Some studies show ketamine can improve mood within hours Anxiety: Though still under research, some evidence shows fast-acting, short-term relief from anxiety symptoms It's worth noting that off-label use means these applications aren't FDA-approved—but doctors may still prescribe ketamine when they believe the benefits outweigh the risks. Risks, side effects, and the darker side of ketamine use Ketamine is generally considered safe when used correctly and under medical supervision. However, it does come with potential side effects, especially when misused or taken recreationally. Common side effects at medical doses include: Drowsiness Double vision Dizziness Confusion Nausea and vomiting Uneasiness or restlessness Less common but serious risks include: Heart and blood vessel instability: Temporary spikes or drops in heart rate and blood pressure Respiratory depression: Risky if overdosed or injected too quickly Emergence reactions: Confusion or agitation during recovery Increased intracranial pressure: Particularly risky for people with brain injuries Liver dysfunction: In some cases, ketamine use has been linked to liver damage Cognitive effects: Some studies suggest thinking and memory deficits, especially in children And because of its dissociative and hallucinogenic effects, ketamine is also misused recreationally and has unfortunately been used in instances of drug-facilitated assault. One step to a healthier you—join Times Health+ Yoga and feel the change
Time of India
13 hours ago
- Time of India
Second patient death reported with gene therapy for muscular dystrophy
Washington: Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy . Sarepta reported the death over the weekend and provided additional details about its response, which includes pausing shipments of the therapy, Elevidys, for older patients who are no longer able to walk. The one-time treatment is approved for children with a genetic variant of Duchenne's muscular dystrophy, which causes weakness, loss of mobility and early death in males. Elevidys is the first gene therapy approved in the U.S. for the rare muscle-wasting condition, but it has faced scrutiny since its accelerated approval in 2023. The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a larger dose of the therapy. Sarepta said it would pause a study in those patients and assemble an expert panel to recommend new safety protocols for taking the drug. Those changes are expected to include increased use of immune-system suppressing drugs, company executives said Monday. The liver injury associated with the therapy is thought to be connected to the immune system's response. Sarepta said it was cooperating with the Food and Drug Administration, which would have to sign off on any changes to the product's use. Elevidys received expedited approval despite concerns from some FDA scientists about its effectiveness in treating Duchenne's. The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still walking. Shares of the Cambridge, Massachusetts-based company fell more than 42% to close at about $21 in trading. Wall Street analysts speculated that FDA officials, including new vaccine chief Dr. Vinay Prasad, might impose more restrictions on the drug or even block its use. Prasad has been highly critical of the therapy since its approval under the agency's previous leadership. "Now with two deaths reported in this segment of the market, it seems incrementally more possible that the FDA could step in and remove the therapy from the market in non-ambulatory patients," said Leerink Partners analyst Joseph Schwartz, in a Sunday research note. Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion.
